AKT1 and T-cell acute lymphoblastic leukemia: Our findings suggested that multiple Akt targeting by drugs with different mechanism of action could represent a new promising treatment for T-cell acute lymphoblastic leukemia patients with PI3K/Akt/mTOR pathway hyperactivation.